A process of making tablets, comprising: compressing a pre-tabletting material in a die at a pressure of greater than or equal to 1 ton/cm 2 to form a tablet, wherein an internal surface of the die is lubricated with at least one lubricant, and said pre-tabletting material comprises at least one therapeutic agent and at least one pharmaceutically acceptable polymer; and ejecting said tablet from said die[[,]] wherein: said pre-tabletting material does not include: any therapeutic agent that is denaturalized or inactivated when compressed at a pressure of greater than or equal to 1 ton/cm 2, any low molecule active ingredient the elution of which is delayed when compressed at a pressure of greater than or equal to 1 ton/cm 2, or any therapeutic agent that is affected by said at least one lubricant; said pre-tabletting material comprises a solid dispersion of said therapeutic agent in a matrix, and said matrix comprises said pharmaceutically acceptable polymer; said pre-tabletting material comprises at least 30% by weight of said at least one pharmaceutically acceptable polymer; said at least one lubricant comprises sodium stearyl fumarate; and said pre-tabletting material comprises less than 0.2 weight % lubricant. compressing a pre-tabletting material in a die at a pressure of greater than or equal to 1 ton/cm 2 to form a tablet, wherein an internal surface of the die is lubricated with at least one lubricant, and said pre-tabletting material comprises at least one therapeutic agent and at least one pharmaceutically acceptable polymer; and ejecting said tablet from said die[[,]] wherein: said pre-tabletting material does not include: any therapeutic agent that is denaturalized or inactivated when compressed at a pressure of greater than or equal to 1 ton/cm 2, any low molecule active ingredient the elution of which is delayed when compressed at a pressure of greater than or equal to 1 ton/cm 2, or any therapeutic agent that is affected by said at least one lubricant; said pre-tabletting material comprises a solid dispersion of said therapeutic agent in a matrix, and said matrix comprises said pharmaceutically acceptable polymer; said pre-tabletting material comprises at least 30% by weight of said at least one pharmaceutically acceptable polymer; said at least one lubricant comprises sodium stearyl fumarate; and said pre-tabletting material comprises less than 0.2 weight % lubricant. said pre-tabletting material does not include: any therapeutic agent that is denaturalized or inactivated when compressed at a pressure of greater than or equal to 1 ton/cm 2, any low molecule active ingredient the elution of which is delayed when compressed at a pressure of greater than or equal to 1 ton/cm 2, or any therapeutic agent that is affected by said at least one lubricant; said pre-tabletting material comprises a solid dispersion of said therapeutic agent in a matrix, and said matrix comprises said pharmaceutically acceptable polymer; said pre-tabletting material comprises at least 30% by weight of said at least one pharmaceutically acceptable polymer; said at least one lubricant comprises sodium stearyl fumarate; and said pre-tabletting material comprises less than 0.2 weight % lubricant.